Iridex says two-year study shows MicroPulse TLT lowers intraocular pressure in early-to-advanced glaucoma
IRIX•Iridex highlighted a published two-year independent retrospective study reporting sustained eye-pressure control with MicroPulse transscleral laser therapy across early to advanced glaucoma. The study also reported lower medication reliance, high treatment success and no safety issues or vision loss during follow-up.
1. Study findings
Iridex highlighted publication of a two-year independent retrospective study on MicroPulse transscleral laser therapy for primary glaucoma. The study reported sustained eye-pressure control and lower reliance on medications across early to advanced disease stages, with high treatment success and no reported safety issues or vision loss during follow-up. Its findings support positioning MicroPulse TLT earlier in the glaucoma treatment pathway, potentially expanding the addressable market for Cyclo G6 systems.
